EGFR and chronic myelogenous leukemia, BCR-ABL1 positive: Well-known examples are (i) imatinib - a selective inhibitor of the abnormal BCR-ABL fusion kinase, characteristic of chronic myeloid leukemia (CML); (ii) bortezomib - a selective inhibitor of the 26S proteasome, vital for the survival of multiple myeloma (MM) cells due to their increased demand for protein turnover; and (iii) epidermal growth factor receptor (EGFR) inhibitors, such as erlotinib and gefitinib, approved for non-small cell lung cancer (NSCLC) (2).